Literature DB >> 17376645

Changes in survival during the past two decades for breast cancer at the Kyoto University Hospital.

M Ueno1, T Kiba, T Nishimura, T Kitano, K Yanagihara, K Yoshikawa, H Ishiguro, S Teramukai, M Fukushima, H Kato, T Inamoto.   

Abstract

AIMS: To report the changes in survival over 20 years of 775 breast cancer women operated between 1982 and 2003 at the Kyoto University Hospital in Japan, reflecting changes in clinical practice over that period.
RESULTS: Survival curves have significantly improved between the periods 1982-1989 and 1990-2003. The 5- and 10-year survival rates between these periods were 80.3% and 85.1%, and 67.5% and 75.0%, respectively. Moreover, there was a difference in overall survival curves of patients of stages II and III, of 35-54 ages, or of positive estrogen receptor (ER) status between these periods.
CONCLUSION: The present study presented the recent advance of the survival rates might be due to the rational development of breast cancer treatment, and suggested the possibility that the patients of stages II and III, of 35-54 ages, or of positive ER status were received benefits by these treatments.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17376645     DOI: 10.1016/j.ejso.2007.01.029

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

1.  Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer.

Authors:  Takayoshi Kiba; Nao Morii; Hirotoshi Takahashi; Shinji Ozaki; Misao Atsumi; Fumi Masumoto; Yoshimi Shitakubo; Hiroyasu Yamashiro
Journal:  Mol Clin Oncol       Date:  2015-11-05

2.  FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion.

Authors:  Masatoyo Nakajo; Yoriko Kajiya; Tomoyo Kaneko; Youichi Kaneko; Takashi Takasaki; Atsushi Tani; Masako Ueno; Chihaya Koriyama; Masayuki Nakajo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-07       Impact factor: 9.236

3.  Defining the survival benchmark for breast cancer patients with systemic relapse.

Authors:  Simon B Zeichner; Tadeu Ambros; John Zaravinos; Alberto J Montero; Reshma L Mahtani; Eugene R Ahn; Aruna Mani; Nathan J Markward; Charles L Vogel
Journal:  Breast Cancer (Auckl)       Date:  2015-04-15

4.  The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery.

Authors:  Takayoshi Kiba; Takashi Inamoto; Tsutomu Nishimura; Masaya Ueno; Kazuhiro Yanagihara; Satoshi Teramukai; Hironori Kato; Masakazu Toi; Masanori Fukushima
Journal:  BMC Cancer       Date:  2008-11-07       Impact factor: 4.430

5.  Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.

Authors:  Takanori Ishida; Takayoshi Kiba; Motohiro Takeda; Kotone Matsuyama; Satoshi Teramukai; Ryota Ishiwata; Norikazu Masuda; Yuichi Takatsuka; Shinzaburo Noguchi; Chikashi Ishioka; Masanori Fukushima; Noriaki Ohuchi
Journal:  Cancer Chemother Pharmacol       Date:  2008-12-12       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.